SLS
SELLAS Life Sciences Group, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.49
−0.35%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$11.67
From 52W high−25.68%
Volume14.53M
Market cap$2.32B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$11.67
From 52W high
−25.68%
Volume
14.53M
Market cap
$2.32B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−86.0x
P/E (TTM)
—
RSI (14)
39.8
MomentumView details →
1D Return
−0.35%
YTD Return
+196.29%
SummaryUpdated Jun 1, 2026
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) is a late-stage biopharmaceutical company founded in 2012 and headquartered in New York, New York. The company went public in 2008 and focuses on developing novel cancer immunotherapies for various cancer indications. SELLAS operates as a clinical-stage biotechnology company with no current commercial products, dedicating its resources to advancing multiple cancer treatment candidates through clinical trials.
Similar companies
Latest newsMore news →
SELLAS Life Sciences Group Inc. stock surged on Thursday, with a year-to-date gain of about 300%.24d agoSellas Life Sciences shares fell 7.66% to $14.28 on August 24, 2026, after a German media report speculated that the REGAL Phase 3 trial may have reached the 80th event needed for final analysis, but the company has not officially confirmed this, leaving retail investors skeptical.27d ago3D Medicines announced that the arbitration award in its favor against SELLAS Life Sciences Group has been fully executed, with SELLAS ordered to pay approximately 7.983 million yuan in costs, which has been received in full.33d ago